{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:08:19Z","timestamp":1791425299447,"version":"4.3.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT\/UID\/4950\/2020, DSAIPA\/DS\/0041\/2020"],"award-info":[{"award-number":["FCT\/UID\/4950\/2020, DSAIPA\/DS\/0041\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007472","name":"Funda\u00e7\u00e3o Luso-Americana para o Desenvolvimento","doi-asserted-by":"publisher","award":["FLAD Life Sciences 2020 Prize"],"award-info":[{"award-number":["FLAD Life Sciences 2020 Prize"]}],"id":[{"id":"10.13039\/501100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which has been suggested as the underlying cause of cognitive impairments. Previous intervention trials investigated the statins\u2019 effects using cognitive outcome measures. However, available outcome measures have led to inconclusive results and there is a need to identify other options. Here, we aimed at investigating alternative outcome measures in a feasibility trial targeting cortical inhibition mechanisms known to be altered in NF1. We explored the neurochemical and physiological changes elicited by lovastatin, with magnetic resonance spectroscopy and transcranial magnetic stimulation (TMS). Fifteen NF1 adults participated in this randomized, triple-blind, placebo-controlled crossover trial (Clinicaltrials.gov NCT03826940) composed of one baseline and two reassessment visits after lovastatin\/placebo intake (60\u00a0mg\/day, 3-days). Motor cortex GABA+ and Glx concentrations were measured using HERMES and PRESS sequences, respectively. Cortical inhibition was investigated by paired-pulse, input\u2013output curve, and cortical silent period (CSP) TMS protocols. CSP ratios were significantly increased by lovastatin (relative: <jats:italic>p<\/jats:italic>\u2009=\u20090.027; absolute: <jats:italic>p<\/jats:italic>\u2009=\u20090.034) but not by placebo. CSP durations showed a negative correlation with the LICI 50\u00a0ms amplitude ratio. Lovastatin was able to modulate cortical inhibition in NF1, as assessed by TMS CSP ratios. The link between this modulation of cortical inhibition and clinical improvements should be addressed by future large-scale studies.<\/jats:p>","DOI":"10.1038\/s41598-022-17873-x","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T09:03:23Z","timestamp":1660554203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial"],"prefix":"10.1038","volume":"12","author":[{"given":"In\u00eas","family":"Bernardino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Dion\u00edsio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"1","key":"17873_CR1","first-page":"1","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann, D. H. et al. Neurofibromatosis type 1. Nat. Rev. Dis. Prim. 3(1), 1\u201317 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"17873_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","volume":"65","author":"SL Hyman","year":"2005","unstructured":"Hyman, S. L., Shores, A. & North, K. N. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65(7), 1037\u20131044 (2005).","journal-title":"Neurology"},{"issue":"6871","key":"17873_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa, R. M. et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415(6871), 526\u2013530 (2002).","journal-title":"Nature"},{"issue":"3","key":"17873_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2008.09.060","volume":"135","author":"Y Cui","year":"2008","unstructured":"Cui, Y. et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135(3), 549\u2013560 (2008).","journal-title":"Cell"},{"issue":"3","key":"17873_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/brain\/aws368","volume":"136","author":"IR Violante","year":"2013","unstructured":"Violante, I. R. et al. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: Genotype\u2013phenotype correlations and functional impact. Brain 136(3), 918\u2013925. https:\/\/doi.org\/10.1093\/brain\/aws368 (2013).","journal-title":"Brain"},{"key":"17873_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cortex.2014.10.019","volume":"64","author":"MJ Ribeiro","year":"2015","unstructured":"Ribeiro, M. J., Violante, I. R., Bernardino, I., Edden, R. A. E. & Castelo-Branco, M. Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex 64, 194\u2013208 (2015).","journal-title":"Cortex"},{"issue":"9","key":"17873_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.0000000000003044","volume":"87","author":"IR Violante","year":"2016","unstructured":"Violante, I. R. et al. GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study. Neurology 87(9), 897\u2013904 (2016).","journal-title":"Neurology"},{"issue":"7","key":"17873_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nn.2559","volume":"13","author":"P Sumner","year":"2010","unstructured":"Sumner, P., Edden, R. A. E., Bompas, A., Evans, C. J. & Singh, K. D. More GABA, less distraction: A neurochemical predictor of motor decision speed. Nat. Neurosci. 13(7), 825\u2013827 (2010).","journal-title":"Nat. Neurosci."},{"issue":"50","key":"17873_CR9","doi-asserted-by":"publisher","first-page":"15721","DOI":"10.1523\/JNEUROSCI.4426-09.2009","volume":"29","author":"RAE Edden","year":"2009","unstructured":"Edden, R. A. E., Muthukumaraswamy, S. D., Freeman, T. C. A. & Singh, K. D. Orientation discrimination performance is predicted by GABA concentration and gamma oscillation frequency in human primary visual cortex. J. Neurosci. 29(50), 15721\u201315726 (2009).","journal-title":"J. Neurosci."},{"issue":"21","key":"17873_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","volume":"15","author":"W Li","year":"2005","unstructured":"Li, W. et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of Neurofibromatosis Type 1. Curr. Biol. 15(21), 1961\u20131967 (2005).","journal-title":"Curr. Biol."},{"issue":"4","key":"17873_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.pediatrneurol.2011.06.016","volume":"45","author":"MT Acosta","year":"2011","unstructured":"Acosta, M. T. et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: Phase I study. Pediatr. Neurol. 45(4), 241\u2013245 (2011).","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"17873_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/acn3.288","volume":"3","author":"CE Bearden","year":"2016","unstructured":"Bearden, C. E. et al. A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. Ann. Clin. Transl. Neurol. 3(4), 266\u2013279 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"17873_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2377-13-131","volume":"13","author":"F Mainberger","year":"2013","unstructured":"Mainberger, F. et al. Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. BMC Neurol. 13, 131 (2013).","journal-title":"BMC Neurol."},{"issue":"24","key":"17873_CR14","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1212\/WNL.0000000000003435","volume":"87","author":"JM Payne","year":"2016","unstructured":"Payne, J. M. et al. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology 87(24), 2575\u20132584 (2016).","journal-title":"Neurology"},{"key":"17873_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-018-0190-z","author":"S Stivaros","year":"2018","unstructured":"Stivaros, S. et al. Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Mol. Autism. https:\/\/doi.org\/10.1186\/s13229-018-0190-z (2018).","journal-title":"Mol. Autism."},{"issue":"11","key":"17873_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1474-4422(13)70227-8","volume":"12","author":"T van der Vaart","year":"2013","unstructured":"van der Vaart, T. et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): A randomised, placebo-controlled trial. Lancet Neurol. 12(11), 1076\u20131083 (2013).","journal-title":"Lancet Neurol."},{"issue":"3","key":"17873_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jama.300.3.287","volume":"300","author":"LC Krab","year":"2008","unstructured":"Krab, L. C. et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial. JAMA J. Am. Med. Assoc. 300(3), 287\u2013294 (2008).","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"12","key":"17873_CR18","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1002\/acn3.50952","volume":"6","author":"JM Payne","year":"2019","unstructured":"Payne, J. M. et al. Reproducibility of cognitive endpoints in clinical trials: Lessons from neurofibromatosis type 1. Ann. Clin. Transl. Neurol. 6(12), 2555\u20132565 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"17873_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1212\/WNL.0000000000002118","volume":"86","author":"T Van Der Vaart","year":"2016","unstructured":"Van Der Vaart, T. et al. Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1. Neurology 86(2), 154\u2013160 (2016).","journal-title":"Neurology"},{"issue":"4","key":"17873_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/09297049.2010.542746","volume":"17","author":"JM Payne","year":"2011","unstructured":"Payne, J. M., Hyman, S. L., Shores, E. A. & North, K. N. Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychol. 17(4), 313\u2013329. https:\/\/doi.org\/10.1080\/09297049.2010.542746 (2011).","journal-title":"Child Neuropsychol."},{"key":"17873_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neuropharm.2012.06.017","volume":"68","author":"PG Enticott","year":"2013","unstructured":"Enticott, P. G. et al. GABAergic activity in autism spectrum disorders: An investigation of cortical inhibition via transcranial magnetic stimulation. Neuropharmacology 68, 202\u2013209 (2013).","journal-title":"Neuropharmacology"},{"issue":"5","key":"17873_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1152\/jn.00704.2012","volume":"109","author":"S Tremblay","year":"2013","unstructured":"Tremblay, S. et al. Relationship between transcranial magnetic stimulation measures of intracortical inhibition and spectroscopy measures of GABA and glutamate\u2009+\u2009glutamine. J. Neurophysiol. 109(5), 1343\u20131349 (2013).","journal-title":"J. Neurophysiol."},{"issue":"23","key":"17873_CR23","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1113\/jphysiol.2011.216978","volume":"589","author":"CJ Stagg","year":"2011","unstructured":"Stagg, C. J. et al. Relationship between physiological measures of excitability and levels of glutamate and GABA in the human motor cortex. J. Physiol. 589(23), 5845\u20135855 (2011).","journal-title":"J. Physiol."},{"key":"17873_CR24","doi-asserted-by":"publisher","first-page":"117394","DOI":"10.1016\/j.neuroimage.2020.117394","volume":"224","author":"K Cuypers","year":"2021","unstructured":"Cuypers, K. & Marsman, A. Transcranial magnetic stimulation and magnetic resonance spectroscopy: Opportunities for a bimodal approach in human neuroscience. Neuroimage 224, 117394 (2021).","journal-title":"Neuroimage"},{"key":"17873_CR25","doi-asserted-by":"publisher","unstructured":"Dion\u00edsio, A., Gouveia, R., Castelhano, J., Duarte, I.C., Santo, G.C., Sargento-Freitas, J., et al. The role of continuous theta burst TMS in the neurorehabilitation of subacute stroke patients: A placebo-controlled study. Front. Neurol. 12. https:\/\/doi.org\/10.3389\/fneur.2021.749798 (2021).","DOI":"10.3389\/fneur.2021.749798"},{"key":"17873_CR26","doi-asserted-by":"publisher","unstructured":"Hupfeld, K.E., Swanson, C.W., Fling, B.W., Seidler, R.D. TMS-induced silent periods: A review of methods and call for consistency. J. Neurosci. Methods. 346. https:\/\/doi.org\/10.1016\/j.jneumeth.2020.108950. (2020)","DOI":"10.1016\/j.jneumeth.2020.108950"},{"issue":"11","key":"17873_CR27","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.clinph.2020.08.016","volume":"131","author":"J Castricum","year":"2020","unstructured":"Castricum, J. et al. Motor cortical excitability and plasticity in patients with neurofibromatosis type 1. Clin. Neurophysiol. 131(11), 2673\u20132681 (2020).","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"17873_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13311-016-0487-6","volume":"14","author":"S Vucic","year":"2017","unstructured":"Vucic, S. & Kiernan, M. C. Transcranial magnetic stimulation for the assessment of neurodegenerative disease. Neurotherapeutics 14(1), 91\u2013106. https:\/\/doi.org\/10.1007\/s13311-016-0487-6 (2017).","journal-title":"Neurotherapeutics"},{"key":"17873_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuroscience.2020.11.011","volume":"452","author":"MC Ferland","year":"2021","unstructured":"Ferland, M. C. et al. Transcranial magnetic stimulation and H1-magnetic resonance spectroscopy measures of excitation and inhibition following lorazepam administration. Neuroscience 452, 235\u2013246 (2021).","journal-title":"Neuroscience"},{"issue":"1","key":"17873_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00221-006-0365-2","volume":"173","author":"MN McDonnell","year":"2006","unstructured":"McDonnell, M. N., Orekhov, Y. & Ziemann, U. The role of GABAB receptors in intracortical inhibition in the human motor cortex. Exp. Brain Res. 173(1), 86\u201393 (2006).","journal-title":"Exp. Brain Res."},{"key":"17873_CR31","doi-asserted-by":"publisher","unstructured":"Neurofibromatosis: Conference Statement. Arch Neurol. 45(5), 575\u2013578 https:\/\/doi.org\/10.1001\/archneur.1988.00520290115023 (1988).","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"17873_CR32","volume-title":"Manual for the Intelligence Scale for Adults","author":"D Wechsler","year":"2008","unstructured":"Wechsler, D. Manual for the Intelligence Scale for Adults (Cegoc-Tea, 2008)."},{"issue":"1","key":"17873_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0028-3932(71)90067-4","volume":"9","author":"RC Oldfield","year":"1971","unstructured":"Oldfield, R. C. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia 9(1), 97\u2013113 (1971).","journal-title":"Neuropsychologia"},{"key":"17873_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/brain\/awn347","volume":"132","author":"L De Beaumont","year":"2009","unstructured":"De Beaumont, L. et al. Brain function decline in healthy retired athletes who sustained their last sports concussion in early adulthood. Brain 132, 695\u2013708 (2009).","journal-title":"Brain"},{"issue":"5","key":"17873_CR35","doi-asserted-by":"publisher","first-page":"e0177560","DOI":"10.1371\/journal.pone.0177560","volume":"12","author":"M Pennisi","year":"2017","unstructured":"Pennisi, M. et al. Cortical involvement in celiac disease before and after long-term gluten-free diet: A Transcranial Magnetic Stimulation study. PLoS One 12(5), e0177560 (2017).","journal-title":"PLoS One"},{"issue":"1","key":"17873_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jneumeth.2007.12.005","volume":"169","author":"L S\u00e4is\u00e4nen","year":"2008","unstructured":"S\u00e4is\u00e4nen, L. et al. Factors influencing cortical silent period: Optimized stimulus location, intensity and muscle contraction. J. Neurosci. Methods 169(1), 231\u2013238 (2008).","journal-title":"J. Neurosci. Methods"},{"key":"17873_CR37","doi-asserted-by":"publisher","unstructured":"Silva G, Duarte IC, Bernardino I, Marques T, Violante IR, Castelo-Branco M. Oscillatory motor patterning is impaired in neurofibromatosis type 1: A behavioural, EEG and fMRI study. J. Neurodev. Disord. 10(1). https:\/\/doi.org\/10.1186\/s11689-018-9230-4 (2018).","DOI":"10.1186\/s11689-018-9230-4"},{"key":"17873_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuroimage.2019.01.056","volume":"189","author":"MG Saleh","year":"2019","unstructured":"Saleh, M. G. et al. Multi-vendor standardized sequence for edited magnetic resonance spectroscopy. Neuroimage 189, 425\u2013431 (2019).","journal-title":"Neuroimage"},{"issue":"1","key":"17873_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/mrm.26233","volume":"76","author":"KL Chan","year":"2016","unstructured":"Chan, K. L., Puts, N. A. J., Sch\u00e4r, M., Barker, P. B. & Edden, R. A. E. HERMES: Hadamard encoding and reconstruction of MEGA-edited spectroscopy. Magn. Reson. Med. 76(1), 11\u201319 (2016).","journal-title":"Magn. Reson. Med."},{"issue":"6","key":"17873_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/mrm.1910380611","volume":"32","author":"DL Rothman","year":"1997","unstructured":"Rothman, D. L., Behar, K. L., Prichard, J. W. & Petroff, O. A. C. Homocarnosine and the measurement of neuronal pH in patients with epilepsy. Magn. Reson. Med. 32(6), 924\u2013929. https:\/\/doi.org\/10.1002\/mrm.1910380611 (1997).","journal-title":"Magn. Reson. Med."},{"issue":"5","key":"17873_CR41","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jmri.24903","volume":"42","author":"AD Harris","year":"2015","unstructured":"Harris, A. D., Puts, N. A. J. & Edden, R. A. E. Tissue correction for GABA-edited MRS: Considerations of voxel composition, tissue segmentation and tissue relaxations. J. Magn. Reson. Imaging 42(5), 1431\u20131440 (2015).","journal-title":"J. Magn. Reson. Imaging"},{"issue":"6","key":"17873_CR42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30(6), 672\u2013679 (1993).","journal-title":"Magn. Reson. Med."},{"issue":"12","key":"17873_CR43","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/npp.2016.260","volume":"42","author":"J Naaijen","year":"2017","unstructured":"Naaijen, J. et al. Fronto-striatal glutamate in autism spectrum disorder and obsessive compulsive disorder. Neuropsychopharmacology 42(12), 2456\u20132465 (2017).","journal-title":"Neuropsychopharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17873-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17873-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17873-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:54:00Z","timestamp":1669359240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17873-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17873"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17873-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13814"}}